FDA ap­proves can­cer ra­di­a­tion drug Aze­dra, send­ing Prog­en­ics stock north

Prog­en­ics of­fi­cial­ly got a thumbs up from the FDA on its can­cer ra­di­a­tion ther­a­py Aze­dra, send­ing the New York com­pa­ny’s stock climb­ing Mon­day af­ter­noon. The drug was ap­proved to treat rare and ex­treme­ly lethal adren­al gland can­cers for which there was no ap­proved treat­ments. Un­til now.

Specif­i­cal­ly, Aze­dra will treat pheocro­mo­cy­toma and para­gan­glioma, neu­roen­docrine tu­mors that form from the same type of tis­sue. The five-year sur­vival rate of un­re­sectable cas­es can be as low as 12%. This new drug is a ra­dio­ther­a­py that goes af­ter these tu­mors with a high, specif­i­cal­ly tar­get­ed dose. The FDA gave it an or­phan drug des­ig­na­tion, fast track sta­tus, and break­through ther­a­py des­ig­na­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER